J Korean Diabetes.  2019 Mar;20(1):6-9. 10.4093/jkd.2019.20.1.6.

Management of Hyperglycemia in Type 2 Diabetes: A Summary of New Consensus Report from the American Diabetes Association and the European Association for the Study of Diabetes in 2018

• Kim JM
• Kim SS

• KMID: 2442347
• DOI: http://doi.org/10.4093/jkd.2019.20.1.6

Abstract

In 2018, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published a consensus recommendation on management of hyperglycemia. This consensus report emphasized the need for patient-centered management considering multimorbidity and individual patient preferences and barriers. Patients with type 2 diabetes with established atherosclerotic cardiovascular disease who fail to control blood glucose with the initial glucose-lowering medication are recommended a sodium-glucose cotransporter 2 (SGLT2) inhibitor or a glucagon-like peptide 1 (GLP-1) receptor agonist. For patients with chronic kidney disease and heart failure, SGLT2 inhibitors are recommended. In patients who need an injectable medication, GLP-1 receptor agonists are the preferred choice over insulin. In this section, we summarize "Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)."

Keyword

Atherosclerosis; Cardiovascular disease; Diabetes mellitus; type 2; Hyperglycemia; Patient-centered care

MeSH Terms

Atherosclerosis
Blood Glucose
Cardiovascular Diseases
Comorbidity
Consensus*
Diabetes Mellitus
Glucagon-Like Peptide 1
Glucagon-Like Peptide-1 Receptor
Heart Failure
Humans
Hyperglycemia*
Insulin
Patient Preference
Patient-Centered Care
Renal Insufficiency, Chronic
Blood Glucose
Glucagon-Like Peptide 1
Glucagon-Like Peptide-1 Receptor
Insulin

Reference

1. Riddle MC, Gerstein HC, Holman RR, Inzucchi SE, Zinman B, Zoungas S, Cefalu WT. A1C targets should be personalized to maximize benefits while limiting risks. Diabetes Care. 2018; 41:1121–1124.

2. American Diabetes Association. 9. Cardiovascular disease and risk management: standards of medical care in diabetes-2018. Diabetes Care. 2018; 41:Suppl 1. S86–104.

3. Gæde P, Oellgaard J, Carstensen B, Rossing P, Lund-Andersen H, Parving HH, Pedersen O. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the steno-2 randomised trial. Diabetologia. 2016; 59:2298–2307.

4. Khunti K, Kosiborod M, Ray KK. Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: time to overcome multifactorial therapeutic inertia? Diabetes Obes Metab. 2018; 20:1337–1341.

5. Gregg EW, Sattar N, Ali MK. The changing face of diabetes complications. Lancet Diabetes Endocrinol. 2016; 4:537–547.

6. Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018; 41:2669–2701.